Promising new immunotherapy combination for advanced kidney cancer
The first results from a phase 2 study (FRACTION-RCC) looking [...]
Intermittent immunotherapy in patients with metastatic kidney cancer
The combination of ipilimumab/nivolumab is approved for patients as a [...]
PRISM study highlights possibility of reducing dose of immunotherapy
The CheckMate-214 clinical trial was the first study to show [...]
Triple combination for previously untreated advanced non-clear cell kidney cancer
The COSMIC-313 study previously showed improved survival when combining cabozantinib [...]
Triple combination improves survival in patients with advanced kidney cancer
Results from the phase 3 COSMIC-313 trial showed that adding [...]
Brain metastases from kidney cancer treated with first-line therapies
A recent study looked at the outcomes of patients with [...]
Adjuvant nivolumab plus ipilimumab for localised kidney cancer
In this randomised phase 3 trial, the effectiveness and safety [...]
How time of day of immunotherapy infusion affects kidney cancer outcomes
Recent studies have suggested that the time of day when [...]
ASCO GU 2023: A triple combination for previously untreated kidney cancer patients
At the American Society of Clinical Oncology Genitourinary Cancers Conference [...]
ASCO GU 2023: Treatment-free survival for advanced kidney cancer patients on nivolumab and salvage nivolumab/ipilimumab
In this study presented at the American Society of Clinical [...]
